UnitedHealth names Wayne DeVeydt as CFO
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Justin Timberlake speaks of 'debilitating' illness amid big spike in tick bites
As Americans head outdoors to enjoy the warm weather, more and more are being sickened by ticks, tiny creatures that can transmit a number of serious diseases. Justin Timberlake announced on July 31, that he is one of the estimated 476,000 people that are diagnosed with and treated for Lyme disease each year, an illness often transmitted through tick bites that Timberlake called "relentlessly debilitating." Meanwhile, emergency room visits related to tick bites have spiked in 2025, reaching their highest level in five years, according to the CDC's Tick Bite Data Tracker. The CDC reported by July 6 that the number of emergency department visits for tick bites had already exceeded nearly 10 years of July records, with 92 visits per 100,000 reported across the nation. Children ages 0 to 9 and people over the age of 70 were the most common of these ER visitors. Why is this tick season so bad? Climate change is one of the main factors impacting tick populations, according to experts at the Binghamton University Tick-borne Disease Center. 'Ticks can now move further north than they could before and establish populations,' Mandy Roome, associate director of the center, has said. 'Going back maybe 15 or 20 years ago, there wasn't much of an issue. Ticks were still around, people still got tick-borne diseases, but it wasn't quite the problem that it is now. We're also having really mild winters. Deer ticks are active anytime it's over 39 degrees, so we have a lot longer active periods for ticks now, unfortunately.' Roome said land use can also affect the tick population. She said construction activity can create new habitats for animals like mice, which can pass on pathogens to ticks. What is Lyme disease? Justin Timberlake shares 'debilitating' diagnosis 'The deer, the mice—when their ranges and numbers increase, we absolutely are going to see an expansion of ticks," Cassandra Pierre, an assistant professor of infectious diseases at the Boston University's Chobanian & Avedisian School of Medicine has said. "And longer warmer weather also allows for there to be more exposure to ticks, because people are out more." Why are tick bites dangerous? Ticks can carry several diseases capable of infecting humans and animals. People typically get Lyme disease, for example, when they are bitten by a tick carrying borrelia bacteria, according to the Mayo Clinic. Humans can also contract a variety of other pathogens from ticks, according to the CDC, including: Anaplasmosis Babesiosis Bourbon virus Colorado tick fever Ehrlichiosis Hard tick relapsing fever Heartland virus Lyme disease Powassan virus Rickettsia parkeri rickettsiosis Rocky Mountain spotted fever Soft tick relapsing fever STARI Tularemia 364D rickettsiosis How to prevent tick bites If you expect to be in an area where ticks live, such a park, backyard or campsite, be extra careful when venturing outside. Ticks can be a year-round annoyance, but they are most active in the warmer months of April through September. Where are ticks found? Maps show where the disease-carrying parasites live Contributing: Janet Loehrke This article originally appeared on USA TODAY: Tick bites way up as Justin Timberlake warns of Lyme disease Solve the daily Crossword
Yahoo
24 minutes ago
- Yahoo
Connecticut Sun will reportedly be sold for $325M and could relocate to Boston by 2027
The Connecticut Sun could be on the move by 2027 after a group led by Celtics minority owner Steve Pagliuca reportedly reached a deal to purchase the WNBA franchise for $325 million, according to the Boston Globe. [Join or create a Yahoo Fantasy Football league for the 2025 NFL season] The $325 million would be the highest price ever paid for a professional women's team. The deal, which will require approval from the WNBA's Board of Governors, would see Pagliuca spend $100 million for a new practice facility in Boston and for the Sun to move from Uncasville, Connecticut. This story will be updated.
Yahoo
24 minutes ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
